Journal Mobile Options
Table of Contents
Vol. 87, No. 3, 2011
Issue release date: October 2011
Urol Int 2011;87:288–292

Pilot Study of the Association between the HLA Region and Testicular Carcinoma among Croatian Patients

Gotovac K. · Grubic Z. · Kastelan Z. · Stingl K. · Kulis T. · Krhen I. · Hudolin T. · Kastelan M. · Zunec R.
aTissue Typing Center, and bDepartment of Urology, University Hospital Centre Zagreb, Zagreb, Croatia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: To analyze the distribution of HLA alleles and HLA microsatellite alleles in Croatian patients with testicular carcinoma, compare it with that of healthy controls and investigate whether the polymorphism within the HLA region could be associated with the development of testicular cancer. Methods: Genomic DNA was isolated from the peripheral blood of 24 patients with testicular germ cell tumors (TGCT). Patients and controls were typed for HLA class I and class II polymorphism by the PCR-SSO method. Nine HLA microsatellites were analyzed by PCR and electrophoresis in an automated sequencer. Results: No significant deviation in the distribution of frequencies at HLA class I alleles was observed between patients and controls. Among HLA class II alleles, a statistically significant increase in the frequency of the HLA-DPB1*1701 allele was found among patients. The frequency of the HLA-DRB1*07-DQA1*0201-DQB1*0202 haplotype was increased in patients in comparison to the controls. Analysis of HLA microsatellites showed an increased frequency of D6S291-3 allele (pcorr = 0.0455, OR = 3.05) among patients. Conclusions: The observed association of the disease and the DPB1*1701 allele as well as with the D6S291-3 allele suggests that this part of the HLA region might be involved in the pathogenesis of TGCT. Our data provide a basis for further studies about the correlation between the HLA region and testicular cancer.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Lin K, Sharangpani R: Screening for Testicular Cancer: an evidence review for the US Preventive Services Task Force. Ann Intern Med 2010;153:396–399.

    External Resources

  2. Croatian National Cancer Registry, Croatian National Institute of Public Health: Cancer Incidence in Croatia 2008, Bulletin No 33. Croatian National Institute of Public Health, 2010.
  3. Oliver RTD, Hope-Stone HF, Blandy JP: Possible new approaches to the management of seminoma of the testis. Br J Urol 1984;56:729–733.
  4. Dieckmann KP, Pichlmeier U: The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer 1997;80:1954–1960.
  5. Dong C, Lonnstedt I, Hemminki K: Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 2001;37:1878–1885.
  6. Sonneveld DJ, Holzik MF, Nolte IM, et al: Testicular carcinoma and HLA class II genes. Cancer 2002;95:1857–1863.
  7. Holzik L, Sijmons RH, Sleijfer DT, et al: Syndromic aspects of testicular carcinoma. Cancer 2003;97:984–992.
  8. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 1997;337:242–253.
  9. Oliver RTD, Stephenson CA, Parkinson MC, et al: Germ cell tumors of the testicle: a model of MHC influence on human malignancy. J Immunogenet 1986;13:85–92.
  10. Nedospasov SA, Udalova IA, Kuprash DV, et al: DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. J Immunol 1991;147:1053–1059.
  11. Faulkner SW, Friedlander ML: Microsatellite instability in germ cell tumors of the testis and ovary. Gynecol Oncol 2000;79:38–43.
  12. Gourraud PA, Mano S, Barnetche T, et al: Integration of microsatellite characteristics in the MHC region: a literature and sequence based analysis. Tissue Antigens 2004;64:543–555.
  13. Grubić Z, Štingl K, Žunec R: Linkage disequilibrium between human leucocyte antigen-B and closely linked microsatellites in the Croatian population. Tissue Antigens 2007;69:86–94.
  14. Woolf B: On estimating the relation between blood group and disease. Ann Hum Genet 1955;19:251–253.
  15. Nishimura K, Miura H, Yasunaga Y: HLA antigens in patients with testicular germ cell tumors. Hinyokika Kiyo 1996;42:95–99.
  16. Özdemir E, Kakehi Y, Mishina M: High-resolution HLA-DRB1 and DQB1 genotyping in Japanese patients with testicular germ cell carcinoma. Br J Cancer 1997;76:1348–1352.
  17. Flores H, Alaez C, Manzanares F, et al: Analysis of MHC microsatellites in children with acute leukemia and Down syndrome. Hum Immunol 2003;64:S141.

    External Resources

  18. Feenstra M, Verdaasdonk K, Van der Zwan AW, et al: Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression. Lab Invest 2000;80:405–414.
  19. Fang M, Chen R, Cai Q, et al: Association of HLA genes with ankylosing spondylitis in Han population of eastern china. Scand J Immunol 2007;65:559–566.
  20. Dharam PS, Jianping L, Kewu L: Genetics of rheumatoid arthritis: two separate regions in the major histocompatibility complex contribute to susceptibility to RA. Immunol Lett 1999;69:301–306.
  21. Bateman AC, Howell WM: Human leukocyte antigens and cancer: is it in our genes? J Pathol 1999;188:231–236.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50